NASDAQ
$47.38
$47.38

Overview

Price performance
Low
$43.24
High
$51.11
Market closed. Last updated: Nov 4, 2026, 9:00 PM UTC
$
47.38
5.18 (12.27%)
Average, 50 days
$51.89
$54.33
Open
$43.32
Previous close
$42.20
52-week high
$93.61
Aug 11, 2026 (3 months ago)
52-week low
$22.31
Oct 1, 2026 (2 months ago)
112.37%

Valuation & Estimates

Earnings

Financials

Insider Trading

Peer Analysis

Insights & Activity

Market Cap
4.24B
Volume
4 808 598
Total Return (3M)
-46.39%
Total Return (1Y)
69.76%
11.76
Sector
Healthcare
Links
Tags
Healthcare
Medical - Pharmaceuticals
NASDAQ
US
About
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.